Profile for New Zealand Patent: 759953

US Patent Family Members and Approved Drugs for New Zealand Patent: 759953

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Jan 30, 2039	Meitheal	CONTEPO	fosfomycin disodium

NZ759953 (New Zealand): Scope, Claims, and Patent Landscape

Last updated: April 26, 2026

What is NZ759953’s subject matter and who holds it?

No response is provided because the request requires the patent’s bibliographic data (assignee/owner, title, filing dates), claim set text, and legal status. Those items are not contained in the prompt, and producing a complete and accurate scope and claims analysis without them would be unreliable.

What claims define the scope of protection in NZ759953?

No response is provided because the claim language is necessary to map scope elements (independent claims, dependent claim fallbacks, claim construction cues, product vs method claims, genus vs species coverage). The claim text is not supplied in the prompt.

How broad is the protection: compound, formulation, use, or process?

No response is provided because the scope must be derived from the claim categories and wording (for example: “a compound of formula,” “a pharmaceutical composition comprising,” “use for treating,” “process for preparing,” and any Markush-style ranges). The prompt does not include claim categories or key claim terms.

What is the New Zealand legal status and remaining term for NZ759953?

No response is provided because remaining term depends on filing date, priority, any PTE/extension mechanism applicable in New Zealand, and whether the patent is active, lapsed, or expired. Those details are not present in the prompt.

What is the related global family and how does it shape the New Zealand scope?

No response is provided because landscape analysis requires identifying the family members (WO/EP/US/CN equivalents), then comparing claim sets and priority dates to determine which inventions were carried into NZ and how breadth was negotiated.

Which third-party patents could block or design around NZ759953 in New Zealand?

No response is provided because an enforceability and freedom-to-operate view requires a search of New Zealand filings and cited prior art against the exact claim boundaries in NZ759953, none of which are provided.

What does the claim-to-prior-art mapping imply for validity risk?

No response is provided because validity risk analysis requires the actual claims and a list of cited documents (XN/Y/X categories) and/or closest prior art patents and publications. These are not included in the prompt.

What is the competitive patent landscape by technology layer (drug substance vs formulation vs method of use)?

No response is provided because layering depends on the specific claim structure (for example, whether protection is anchored in a specific active, a polymorph, a salt, a release profile, or a biomarker-based indication). The claim set is not supplied.

Key Takeaways

No response is provided because the underlying patent record (bibliographic details, claim text, and legal status) is missing.

FAQs

1. What does NZ759953 protect?
   No response is provided.

2. Which claims are the narrowest and which are the broadest?
   No response is provided.

3. Is NZ759953 tied to a specific indication or a broader class of uses?
   No response is provided.

4. How much time remains on NZ759953 in New Zealand?
   No response is provided.

5. Which other New Zealand or family patents are most relevant for freedom-to-operate?
   No response is provided.

---

References

[1] None (no source documents were provided in the prompt).